<DOC>
	<DOCNO>NCT02576964</DOCNO>
	<brief_summary>This study evaluate efficacy safety capecitabine ( Xeloda ) combination peginterferon alfa-2a ( Pegasys ) participant advance liver cancer prior treatment . The anticipated time study treatment disease progression , target sample size 43 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Peginterferon Alfa-2a ( Pegasys ) Treatment-Naive Participants With Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults 18 75 year age Locally advance metastatic liver cancer measurable disease eligible standard therapy Previous treatment liver cancer Main portal vein involvement Bone , brain , leptomeningeal metastasis Clinically significant cardiac disease Malabsorption syndrome lack physical integrity upper gastrointestinal tract History cancer , except basal cell skin cancer situ cancer cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>